TransCode Therapeutics Treats First Patients in Phase 1 Trial

TransCode Therapeutics, Inc. has initiated a Phase 1 clinical trial for its lead candidate, TTX-MC138, administering the first doses to two patients. Several other patients have been assessed for potential enrollment in this multicenter, open-label, and dose-escalation study, which aims to evaluate the safety and tolerability of TTX-MC138 in patients with metastatic cancer.

Sue Duggan, Senior Vice President of Operations at TransCode, expressed excitement over this development, highlighting it as a crucial step in the TTX-MC138 clinical program. Duggan underscored that TTX-MC138, a first-in-class therapeutic candidate, demonstrated evidence of effectively reaching metastatic lesions in previous Phase 0 clinical trials.

TTX-MC138 is an antisense oligonucleotide conjugated to TransCode’s proprietary TTX delivery system, specifically designed to inhibit microRNA-10b, a molecule implicated in the metastasis of various cancers. TransCode posits that this candidate is the first in clinical development to target a molecule responsible for metastatic disease across multiple cancer types, regardless of metastasis location. The successful development of TTX-MC138 has the potential to significantly improve patient outcomes for a range of cancers, including breast, pancreatic, ovarian, colon, and lung cancers.

The ongoing Phase 1 trial is structured into two main phases: dose-escalation and dose-expansion. The dose-escalation phase's primary goal is to assess the safety and tolerability of increasing doses of TTX-MC138. Following this, the dose-expansion phase will further evaluate the safety, tolerability, and anti-tumor activity of TTX-MC138 in specific tumor types selected based on preliminary results from the dose-escalation phase. While the primary goal is to establish safety and tolerability, the trial may also provide early indications of the drug's clinical activity.

TransCode, a clinical-stage oncology company, is dedicated to combating metastatic disease through the innovative design and delivery of RNA therapeutics using its proprietary TTX nanoparticle platform. TTX-MC138 is the company's foremost therapeutic candidate, concentrating on metastatic tumors that overexpress microRNA-10b, a well-documented biomarker associated with metastasis. TransCode is also working on a portfolio of other RNA therapeutic candidates aimed at overcoming RNA delivery challenges and unlocking treatment potential for various novel genetic targets relevant to different cancers.

The progress of TTX-MC138 signals a potentially transformative approach to treating metastatic cancer, offering hope for more effective interventions in the future.